A patient treated for hypertension with labetalol developed left ventricular failure. When the drug was withdrawn and the BP controlled with 2 other agents, the signs of heart failure regressed. The The arterial pressure did not fall after the operation. He was re-admitted one month after discharge with further chest pain, which was shown to be due to a fresh inferior myocardial infarction. Thereafter he was treated with propranolol, methyldopa and chlorthalidone, with variable control of his blood pressure.
Summary
A patient treated for hypertension with labetalol developed left ventricular failure. When the drug was withdrawn and the BP controlled with 2 other agents, the signs of heart failure regressed. The The arterial pressure did not fall after the operation. He was re-admitted one month after discharge with further chest pain, which was shown to be due to a fresh inferior myocardial infarction. Thereafter he was treated with propranolol, methyldopa and chlorthalidone, with variable control of his blood pressure.
Eighteen months later he was re-admitted because of palpitations, dyspnoea and nocturia. His blood pressure had risen to 210/140 mmHg but there was no change in the fundal appearances. X-rays showed features of left ventricular failure, but there were no fresh ECG changes, and no alteration in serum LDH or AST to suggest a further myocardial infarction. His renal function had deteriorated, the serum creatinine having risen to 159 ,tmol/l from 96 ,umol/l since his previous admission. He was treated with frusemide and spironolactone, and was given labetalol 200 mg thrice daily which was increased to 400 mg thrice daily one week later. Although the BP was reduced to 120/90 mmHg his condition deteriorated despite large doses of frusemide (1 g daily) and spironolactone. He became faint on standing although there was only a 5-mmHg orthostatic fall in BP. Chest X-ray showed increasing evidence of left ventricular failure and there was a small rise in the serum creatinine from 159 ,umol/l to 217 ,umol/l. Labetalol was therefore withdrawn and he was treated with a combination of prazosin (6 mg daily) and clonidine (0-6 mg daily, later increased to 0 9 mg daily). Without any alteration in diuretic therapy his heart failure improved, the dose of frusemide was subsequently reduced and the spironolactone stopped.
When last seen his blood pressure was 150/100 mmHg. Both clinically and radiologically there was no evidence of heart failure.
Discussion
Labetalol has a-blocking properties as well as being a (-blocker (Richards et al., 1974) . It has been credited with the advantage that it lowers arterial pressure without reflex tachycardia and without any reduction in cardiac output (Edwards and Raftery, 1976) . It causes no deterioration in calculated indices of left ventricular function, except at extreme levels of exercise. The a-blocking activity of the drug gives it the theoretical advantage over those which are only (-blockers, particularly in patients with symptoms of and a previous history of heart failure.
In the case reported here labetalol seems to have provoked heart failure. When withdrawn, and the BP controlled with 2 other agents, the radiological and clinical signs of left ventricular failure regressed. It may be speculated that there was a temporary impairment of renal function, although the rise in serum creatinine was very small and he did not develop dependent oedema. When another drug with only vasodilating properties, prazosin, was used, the heart failure resolved. It is possible that the provocation of heart failure in this case was due to the Pblocking effects of labetalol being 4 to 6 times greater than the ac-blocking effects (Brittain and Levy, 1976) .
A recent report that intravenous administration of labetalol produced hypertension (Crofton and Gabriel, 1977) 
